Osisko Development Corp. (NYSE:ODV) is among the 11 Best Gold Stocks to Buy for 2026. Osisko Development Corp. (ODV) Announces $125M Bought Deal Offering On January 27, 2026, TheFly reported that Osisko Development Corp. (NYSE:ODV) announced a $125 million bought deal financing on behalf of a syndicate. National Bank Capital Markets, RBC Capital Markets, and Cantor are serving as co-lead underwriters and co-bookrunners. The underwriters decided to spend $125 million in gross proceeds for 35.31 million co ...

We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Avino Silver & Gold Mines Ltd. stands fourth on our list of high growth stocks. TheFly reported on January 23 that H.C. Wainwright raised its price target for ASM to $12.50 from $7.40 and maintained a Buy rating. The increase followed the company’s announcement of its 2025 production results, with the higher target supported by updated price assumptions and a one-year forward adjustment to the valuation. High-Grade Sil ...

We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. CorMedix Inc. tops our list for being one of the high growth stocks. TheFly reported on January 23 that H.C. Wainwright lowered the price target on CRMD to $13 from $18 while keeping a Buy rating. The adjustment reflects updated guidance for 2026–2027 related to DefenCath. The firm noted that CRMD has now entered a phase where clinical results will play a larger role than commercial performance in shaping the company’s ...

We recently published Jim Cramer Discussed Trump, CEOs & These 10 Stocks. CSX Corporation (NASDAQ:CSX) is one of the stocks Jim Cramer discussed. CSX Corporation (NASDAQ:CSX) is one of the largest railroad companies in America. The shares are up by a modest 13.8% over the past year and by 3.5% year-to-date. Susquehanna raised the firm’s share price target to $39 from $38 and maintained a Neutral rating after the firm’s latest earnings report. The earnings saw CSX Corporation (NASDAQ:CSX) post $3.50 billio ...

Joining us now, George Heel. He's the vice president of commodity research at George, great to have you with us. >> Thanks for having me.>> You know, it's funny that we we had this list of fundamental reasons why the metals would decline today and yet the move has been sort of memeish, which is by definition not pinned by fundamental drivers. So, what did you make of the of the drop today. Of course.Well, I think you know silver has obviously had a outsized move against gold over the last few months and thi ...

公司评级与估值 - Piper Sandler于1月15日将AGNC Investment Corp的目标价维持在11美元，并给予“超配”评级，该评级上调反映了机构抵押贷款支持证券利差收窄，预计将有利于公司未来的有形账面价值 [1] 公司近期动态 - 公司宣布了2026年1月的现金股息为每股0.12美元 [2] - 公司重新任命经济学家Morris Davis博士为薪酬与公司治理委员会的独立董事，其曾担任经济顾问委员会首席住房经济学家，将为公司管理层带来住房和宏观经济政策方面的专业知识 [2][3] 公司业务概况 - AGNC Investment Corp是一家房地产投资信托基金，主要投资于住宅抵押贷款过手证券和抵押贷款担保债券 [4] - 公司业务还涉及投资其他类型的抵押贷款及抵押贷款相关证券，包括信用风险转移证券以及非机构住宅和商业抵押贷款支持证券 [4]

Immunocore Holdings plc (NASDAQ:IMCR) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $100 price target. Earlier, on January 6, UBS also initiated Immunocore Holdings plc (NASDAQ:IMCR) with a Buy rating and a $55 price target. ​Analysts at UBS see significant potential upside for the stock because it is currently trading close to the value of its approved drug Kimmtrak. The firm noted that this ...

公司股价表现与市场关注 - 美光科技股价在过去一年中表现强劲，累计上涨387% [2] - 公司股票受到多位分析师关注，伯恩斯坦和汇丰银行均上调其目标价 [2] - 伯恩斯坦将目标价从270美元上调至330美元，并维持“跑赢大盘”评级 [2] - 汇丰银行将目标价从350美元大幅上调至500美元，并维持“买入”评级 [2] 行业地位与产品优势 - 美光科技是全球少数几家能够生产用于英伟达AI GPU的先进存储芯片的公司之一 [2] - 分析师认为，受数据中心需求驱动，存储芯片价格在2026年将保持强劲，公司将持续受益 [2] - 汇丰银行上调目标价的原因之一是公司具备定价能力 [2] 市场供需与业绩解读 - 吉姆·克莱默将公司业绩与短缺现象联系起来，指出业绩未达预期是因为无法满足需求，而非需求不足 [3] - 克莱默强调，不应误读业绩数据，短缺的存在对美光科技而言并非坏事 [3] - 克莱默在月度电话会议中讨论了市场叙事，指出通常难以同时出现美光科技（动量股）和英伟达股价双双上涨的情况 [3]

公司股价表现与市场关注 - 公司股票是市场表现最佳股票之一 自2025年初以来股价涨幅达三位数百分比 [2] - 2026年 多家分析师讨论了该公司 其中Mizuho将公司目标价从410美元上调至600美元 并维持“跑赢大盘”评级 [2] - 同样在2026年1月 Benchmark将公司目标价从260美元大幅上调至450美元 并维持“买入”评级 [2] 行业供需与价格前景 - 公司正从其NAND和DRAM产品的行业定价权中受益 [2] - 关键驱动因素是NAND晶圆产能预计在2026年和2027年出现短缺 [2] - 产能短缺可能导致2026年NAND价格大幅上涨330% [2] - Benchmark同样将NAND市场产能视为其调整评级的原因之一 [2] 市场观点与讨论 - Jim Cramer在讨论公司时也提到了产能短缺问题 [2] - Cramer指出 公司业绩未达预期是因为无法满足需求 而非需求不足 [3] - Cramer将公司归类为动量股 并讨论了其与英伟达等股票的市场轮动关系 [3]

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential. On January 6, Mineralys Therapeutics announced the late 2025 filing of its NDA for lorundrostat. The company highlighted several clinical milestones, including the completion of three positive trials (Explore-CKD, Launch-HTN, and Advance-HTN), which demonstrated the drug’s 24-hour blood pressure control and safety across diverse patient populations. Additionally, Mineralys remains on track ...